251 related articles for article (PubMed ID: 26184481)
1. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
[TBL] [Abstract][Full Text] [Related]
2. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
3. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
Rouleau C; Curiel M; Weber W; Smale R; Kurtzberg L; Mascarello J; Berger C; Wallar G; Bagley R; Honma N; Hasegawa K; Ishida I; Kataoka S; Thurberg BL; Mehraein K; Horten B; Miller G; Teicher BA
Clin Cancer Res; 2008 Nov; 14(22):7223-36. PubMed ID: 19010839
[TBL] [Abstract][Full Text] [Related]
4. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
5. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
6. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
7. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
[TBL] [Abstract][Full Text] [Related]
8. Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.
Capone E; Piccolo E; Fichera I; Ciufici P; Barcaroli D; Sala A; De Laurenzi V; Iacobelli V; Iacobelli S; Sala G
Oncotarget; 2017 Sep; 8(36):60368-60377. PubMed ID: 28947977
[TBL] [Abstract][Full Text] [Related]
9. Endosialin: a novel malignant cell therapeutic target for neuroblastoma.
Rouleau C; Smale R; Sancho J; Fu YS; Kurtzberg L; Weber W; Kruger A; Jones C; Roth S; Bormann C; Dunham S; Krumbholz R; Curiel M; Wallar G; Mascarello J; Campos-Rivera J; Horten B; Schmid S; Miller G; Teicher BA
Int J Oncol; 2011 Oct; 39(4):841-51. PubMed ID: 21701770
[TBL] [Abstract][Full Text] [Related]
10. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y; Hu J; Wang Y; Peng X; Min J; Wang J; Matthaiou E; Cheng Y; Sun K; Tong X; Fan Y; Zhang PJ; Kandalaft LE; Irving M; Coukos G; Li C
Eur J Cancer; 2018 Feb; 90():111-121. PubMed ID: 29304474
[TBL] [Abstract][Full Text] [Related]
11. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
[TBL] [Abstract][Full Text] [Related]
14. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
16. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
18. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.
Rouleau C; Smale R; Fu YS; Hui G; Wang F; Hutto E; Fogle R; Jones CM; Krumbholz R; Roth S; Curiel M; Ren Y; Bagley RG; Wallar G; Miller G; Schmid S; Horten B; Teicher BA
Int J Oncol; 2011 Jul; 39(1):73-89. PubMed ID: 21537839
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
20. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]